Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of thromBocytopenia With EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients With Immune ThrombocytoPenia- BRIDGING ITP Study

Trial Profile

Treatment of thromBocytopenia With EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients With Immune ThrombocytoPenia- BRIDGING ITP Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2018

At a glance

  • Drugs Eltrombopag (Primary) ; Immune globulin
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Therapeutic Use
  • Acronyms BRIDGING ITP
  • Most Recent Events

    • 14 Jun 2018 Planned End Date changed from 1 Aug 2018 to 1 Jan 2019.
    • 14 Jun 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Jan 2019.
    • 16 Mar 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2018 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top